Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis
Yuan‐Hung Kuo(Chang Gung University), Jing‐Houng Wang(Kaohsiung Chang Gung Memorial Hospital), Tsung‐Hui Hu(National Sun Yat-sen University), Chuan–Mo Lee(Chang Gung University), Hsuan‐Chih Hsu(Kaohsiung Chang Gung Memorial Hospital), Sheng‐Nan Lu(Kaohsiung Chang Gung Memorial Hospital), Chao‐Long Chen, Chi‐Sin Changchien(Kaohsiung Chang Gung Memorial Hospital), Chao‐Hung Hung(Kaohsiung Chang Gung Memorial Hospital), Yu‐Fan Cheng, Chien‐Hung Chen(Kaohsiung Chang Gung Memorial Hospital), Chih‐Yun Lin(Chang Gung University)
Cited by 98
Related Papers
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Metabolic Factors and Risk of Hepatocellular Carcinoma by Chronic Hepatitis B/C Infection: A Follow-up Study in Taiwan
|Gastroenterology|2008|547
Hepatogastroenterology
|Hepatogastroenterology|2012|536